According to filings with the U.S. Securities and Exchange Commission, ReAlta Life Sciences is raising $22,500,017.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Ulrich Thienel played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About ReAlta Life Sciences
ReAlta Life Sciences is a clinical stage biotech company dedicated to harnessing the power of the immune system through its EPICC technology platform, comprised of a family of over 160 engineered peptides, to address life-threatening medical needs. The peptide family leverages one billion years of evolution that has enabled the human astrovirus to inhibit components of the innate immune system. This novel class of therapeutics exploits the virus dual targeting approach and enables the rebalancing of complement and inflammatory processes in the body. The companys pipeline is led by RLS-0071, which has been granted Orphan Drug Designation by the U.S. Food and Drug Administration and European Medicines Agency for the treatment of hypoxic-ischemic encephalopathy (HIE) in neonates. The company launched in 2018, and is located in Norfolk, Virginia.

To learn more about ReAlta Life Sciences, visit http://realtalifesciences.com/

Contact:
Ulrich Thienel, Chief Executive Officer
757-901-0460
https://www.linkedin.com/in/thienel/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.